Longeviti Neuro Solutions Appoints T. Rowe Price CEO Robert W. Sharps to Board of Directors

NodeGuardian · 2026-03-25T05:13:33+00:00

Longeviti Neuro Solutions has appointed Robert W. Sharps to its Board of Directors to enhance strategic planning and expedite initiatives, especially for its ClearFit AI™ platform, as the company specializes in AI-driven solutions for neurological health.

NodeGuardian

2026-03-25 05:13:33

Abstract generation in progress

Longeviti Neuro Solutions, a neurotechnology company, has appointed Robert W. Sharps, CEO and President of T. Rowe Price Group, Inc., to its Board of Directors. Sharps brings extensive experience in global asset management, corporate governance, and strategic growth, aiming to strengthen Longeviti’s strategic planning and accelerate its clinical and commercial initiatives, particularly for its ClearFit AI™ platform. Longeviti focuses on advanced implantable and AI-enabled solutions for neurological health and has FDA-cleared products used in over 4,000 patients globally.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.